Simon J Ellis. Show Affiliations »
Abstract
Mesh: See more » Adjuvants, Immunologic/economicsAdjuvants, Immunologic/therapeutic useCost-Benefit AnalysisHumansInterferon-beta/economicsInterferon-beta/therapeutic useMultiple Sclerosis/drug therapyMultiple Sclerosis/economicsQuality-Adjusted Life YearsUnited Kingdom
Substances: See more » Adjuvants, ImmunologicInterferon-beta
Year: 2002 PMID: 11844551 DOI: 10.1016/s0140-6736(02)07582-7
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321